Entellus Medical (ENTL) Names Jeff Kogl As Vice President Of Business Development And Strategy

PLYMOUTH, Minn., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that Jeff Kogl has been named Vice President of Business Development and Strategy effective immediately. Mr. Kogl will report directly to Entellus Medical's President and CEO, Robert White.

Mr. Kogl joins Entellus with extensive experience in the medical device market creating and executing effective business development and marketing strategies. For the past two years, he was the Vice President of Strategy and Corporate Development at Tornier, a company specializing in the design, development, and commercialization of devices for joint replacement and soft tissue repair. Prior to his tenure at Tornier, Mr. Kogl was the Senior Director of Corporate Development and Portfolio Strategy at Medtronic where he held various business development roles of increasing responsibility from June 2002 to June 2011.

"We are pleased to have Jeff join the Entellus team. With extensive industry experience in strategic planning and business development, he brings strong leadership skills and expertise that will strengthen our overall growth strategies," said Robert White, President and Chief Executive Officer. "I am excited to have him on board as we continue to drive broad adoption of our products and look forward to his contributions to the Company."

"I am delighted to have the opportunity to join Entellus at this exciting point in the Company's growth. I am confident that my experience in identifying new opportunities and building great organizations will enable me to make a valuable contribution to the planning and execution of our commercial growth strategies," said Mr. Kogl.

Mr. Kogl holds an M.B.A. from the University of Minnesota, and a B.A. in Political Science from Stanford University.

About Entellus Medical, Inc.

Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients. The Entellus Medical platform of products provides physicians with solutions to aid in the diagnosis and treatment of patients suffering from chronic sinusitis. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery ("FESS"). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. In addition to its XprESS line of products, Entellus Medical has recently introduced additional products designed to aid in the diagnosis, treatment and post-operative care of patients suffering from chronic sinusitis.

Entellus Medical currently markets its products in the United States, Europe and Canada and sells its products through a direct sales force in the United States and the United Kingdom. For more information, please visit the Company's website at www.entellusmedical.com.
CONTACT: Leigh Salvo 415-513-1281 [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.